Method for Producing Peptide Ace Inhibitors

Abstract

A method for producing ACE Inhibitor peptides from a protein source or plasma is disclosed. The method utilizes proteolysis by intestinal, blood-circulating, or membrane-bound proteases. The initial synthesis step could require obtaining a protein source either from a human or animal. A protease is added to either a given plasma protein or plasma and incubated. Following incubation, the protease activity must be quenched using a protease inhibitor to inactivate the protease. After incubation with protease inhibitor, the solution will contain a mixture of bioactive ACE inhibitory peptides and inert peptides. This mixture may be purified to select for the ACE inhibitory peptides through centrifugation. The mixture may also be sterilized to remove any microbial contaminants. The ACE inhibitory peptides can be mixed with protein powders, incorporated into baked good and put into other food products to provide food products with the added benefit of lowering blood pressure.

1 . A method of making polypeptide angiotensin converting enzyme (ACE) inhibitors from plasma comprising:
 mixing the plasma with at least one serine protease in a ratio of between one ten thousandth and one tenth of the concentration protease concentration to plasma protein concentration;   stirring the mixture of plasma and trypsin to make the polypeptide angiotensin converting enzyme (ACE) inhibitors; and   quenching the at least one serine protease mixed with the plasma.   
     
     
         2 . The method of  claim 1 , wherein the plasma is mixed with at least one serine protease for between 0.1 hours to 24 hours. 
     
     
         3 . The method of  claim 1 , wherein the plasma is mixed with at least one serine protease at 0 degrees to 40 degrees Celsius. 
     
     
         4 . The method of  claim 1 , wherein the plasma comprises serum albumin. 
     
     
         5 . The method of  claim 1 , wherein quenching comprises contacting the at least one serine protease with a protease inhibitor. 
     
     
         6 . The method of  claim 5 , wherein the protease inhibitor is at a concentration of between one ten thousandth and one tenth of the concentration of the at least one serine protease. 
     
     
         7 . The method of  claim 1 , wherein the at least one serine protease is trypsin. 
     
     
         8 . The method of  claim 1 , wherein the at least one serine protease is chymotrypsin. 
     
     
         9 . The method of  claim 1 , wherein the at least one protease is at a concentration of between 1 μg/mL and 1 g/mL. 
     
     
         10 . The method of  claim 1  further comprising:
 incorporating the polypeptide angiotensin converting enzyme (ACE) inhibitors into food product; and 
 a user consuming the food products containing the polypeptide angiotensin converting enzyme (ACE) inhibitors to lower the blood pressure of the user. 
 
     
     
         11 . A method of making polypeptide angiotensin converting enzyme (ACE) inhibitors from blood serum comprising:
 mixing the blood serum with chymotrypsin in a ratio of between one ten thousandth and one tenth of the concentration protease concentration to blood serum protein concentration;   stirring the mixture of blood serum and trypsin to make the polypeptide angiotensin converting enzyme (ACE) inhibitors; and   quenching the at least one serine protease mixed with the blood serum.   
     
     
         12 . The method of  claim 11 , wherein the blood serum is mixed with at least one serine protease for between 0.1 hours to 24 hours. 
     
     
         13 . The method of  claim 11 , wherein the blood serum is mixed with at least one serine protease at 0 degrees to 40 degrees Celsius. 
     
     
         14 . The method of  claim 11 , wherein the blood serum comprises serum albumin. 
     
     
         15 . The method of  claim 11 , wherein quenching comprises contacting the chymotrypsin with a protease inhibitor. 
     
     
         16 . The method of  claim 15 , wherein the protease inhibitor is at a concentration of between one ten thousandth and one tenth of the concentration of the chymotrypsin. 
     
     
         17 . The method of  claim 11 , further comprising contacting the blood serum with trypsin. 
     
     
         18 . The method of  claim 11 , further comprising contacting the blood serum with elastase. 
     
     
         19 . The method of  claim 11 , wherein the chymotrypsin is at a concentration of between 1 μg/mL and 1 g/mL. 
     
     
         20 . The method of  claim 11  further comprising:
 incorporating the polypeptide angiotensin converting enzyme (ACE) inhibitors into food product; and 
 a user consuming the food products containing the polypeptide angiotensin converting enzyme (ACE) inhibitors to lower the blood pressure of the user.